Disclosures for "Impact of Psychiatric Conditions on the Real-world Effectiveness of Eptinezumab Treatment in Patients with Chronic Migraine"
-
Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nevro. Dr. Argoff has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for XGene. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Argoff has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/Abbvie. The institution of Dr. Argoff has received research support from Lilly. Dr. Argoff has received publishing royalties from a publication relating to health care. Dr. Argoff has received publishing royalties from a publication relating to health care. Dr. Argoff has received publishing royalties from a publication relating to health care.
-
Dr. Herzog has nothing to disclose.
-
Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie.
-
Seema Soni-Brahmbhatt has nothing to disclose.
-
Dr. Awad has nothing to disclose.
-
Divya Asher has received personal compensation for serving as an employee of Lundbeck. Divya Asher has received personal compensation for serving as an employee of AbbVie.
-
The institution of Dr. Khan has received research support from Amgen .